Lixisenatide and beinaglutide Lixisenatide and beinaglutide, including EX-BID as discussed earlier, are classified as short-acting GLP-1RAs based on pharmacokinetic characteristics such as clearance half-life and concentration-time distribution
Endothelium, the single-cell layer lining blood vessels, serves a crucial role in various vascular processes, including vascular homeostasis, smooth muscle cell proliferation and thrombus formation/lysis balance (130)
MAO-A is more dominant in the heart, platelets, gut, and certain neurons, while MAO-B is prevalent in astrocytes and specific brain regions, as well as in the heart, intestines, kidneys, and blood vessels.[ref][ref][ref] Variants in the MAOA gene sometimes called the warrior gene can affect neurotransmitter levels and have been linked to changes in mood, aggressiveness, and response to antidepressants
It has not been associated with the more serious potential complications of pharmaceutical GLP-1 agonists, such as pancreatitis or gallbladder problems
Pharmacovigilance is the process of monitoring, investigating, and reporting adverse drug reactions